Home » Stocks » NEO

NeoGenomics, Inc. (NEO)

Stock Price: $36.81 USD -1.08 (-2.84%)
Updated May 13, 2021 3:33 PM EDT - Market open
Market Cap 4.56B
Revenue (ttm) 453.95M
Net Income (ttm) -10.96M
Shares Out 116.20M
EPS (ttm) -0.10
PE Ratio n/a
Forward PE 222.22
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $36.81
Previous Close $37.88
Change ($) -1.08
Change (%) -2.84%
Day's Open 38.35
Day's Range 36.30 - 38.82
Day's Volume 876,156
52-Week Range 25.19 - 61.57

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Spotting bloated toxic stocks on a regular basis and abandoning them at the right time is one of the secrets to a winning investment strategy.

Other stocks mentioned: HHC, HQY, STNE
2 days ago - Zacks Investment Research

FT. MYERS, FL / ACCESSSWIRE / May 10, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced...

2 days ago - Accesswire

These under-the-radar names deserve investors' attention.

Other stocks mentioned: ALG, PRFT
4 days ago - The Motley Fool

NeoGenomics (NEO) delivered earnings and revenue surprises of -500.00% and 2.62%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

NeoGenomics Inc (NASDAQ: NEO) has agreed to acquire the remaining stake in Inivata Ltd, a commercial-stage liquid biopsy platform company headquartered in England. The acquisition follows a $25 million ...

1 week ago - Benzinga

First-Quarter 2021 Results and Highlights: Consolidated revenue increased 9% to $116 million Clinical Services revenue increased 4% to $96 million Pharma Services revenue increased 46% to $19 million Co...

1 week ago - Accesswire

Establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market NeoGenomics exercises option struck in May 2020 to purchase remaining equity stake for $390 million Co...

1 week ago - Accesswire

NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago - Zacks Investment Research

SGT Program will provide KRAS G12C testing to eligible patients at no cost, regardless of insurance type. FT. MYERS, FL / ACCESSWIRE / April 19, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider...

3 weeks ago - Accesswire

FT. MYERS, FL / ACCESSWIRE / April 13, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announce...

1 month ago - Accesswire

Small-cap growth stocks can be thick on potential, but thin in news updates and analysis. Here, we look at seven high-potential small caps, and what the pros have to say about them.

Other stocks mentioned: AHCO, BRBR, GTLS, LOVE, QTWO, RXT
1 month ago - Kiplinger

FT MYERS, FL / ACCESSWIRE / April 7, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to r...

1 month ago - Accesswire

NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

1 month ago - Zacks Investment Research

Clinical Decision Support to Enable Precision Oncology FT. MYERS, FL / ACCESSWIRE / March 24, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and glo...

1 month ago - Accesswire

Clinical Trial Matching Collaboration Will Enhance Identification of Patients with Any Solid Tumo r Harboring an NRG1 Gene Fusion Identified Using NeoGenomics' Advanced Gene Fusion Panels FORT MYERS, FL...

1 month ago - Accesswire

FT. MYERS, FL / ACCESSWIRE / March 1, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced...

2 months ago - Accesswire

Shares of NeoGenomics (NASDAQ:NEO) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share rose 40.00% over the past year to $0.14, which beat the estimate of $0.06.

2 months ago - Benzinga

NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

The S&P 500 Index stocks saw their aggregate trailing 12-month revenue per share increase at a compound average growth rate (CAGR) of 2% per annum over the past five years. The share price of the index ...

Other stocks mentioned: IBN, TPL
3 months ago - GuruFocus

Access to industry-leading genomic database and real-world evidence designed to optimize trial design, site selection, clinical trial matching and translational research Access to industry-leading genom...

3 months ago - GlobeNewsWire

FORT MYERS, FL / ACCESSWIRE / January 6, 2021 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetics testing services and global oncology contract research servi...

4 months ago - Accesswire

FORT MYERS, FL / ACCESSWIRE / January 5, 2021 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetics testing services and global oncology contract research servi...

4 months ago - Accesswire

FT. MYERS, FL / ACCESSWIRE / January 4, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announc...

4 months ago - Accesswire

TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Costco and Twitter

Other stocks mentioned: COST, MKSI, TWTR, ZNGA
4 months ago - CNBC

NeoGenomics remains insulated and differentiated from peers via a plethora of offerings in clinical diagnostics, as a potential market-leader in oncology services. The growth vision looks at consolidati...

4 months ago - Seeking Alpha

NeoGenomics, Inc.'s (NEO) CEO Doug VanOort on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

NeoGenomics (NEO) delivered earnings and revenue surprises of 500.00% and -2.69%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

NeoGenomics (NEO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

6 months ago - Zacks Investment Research

ANIK vs. NEO: Which Stock Is the Better Value Option?

Other stocks mentioned: ANIK
8 months ago - Zacks Investment Research

The oncology reference lab never stopped investing in near- and long-term opportunities. It expects that to pay off -- and soon.

9 months ago - The Motley Fool

NeoGenomics, Inc. (NEO) CEO Doug VanOort on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Shares of NeoGenomics (NASDAQ:NEO) rose 1% after the company reported Q2 results.

9 months ago - Benzinga

NeoGenomics (NEO) delivered earnings and revenue surprises of 55.56% and 1.01%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

These pioneers will be winners however the pandemic plays out.

Other stocks mentioned: BNTX, ILMN
10 months ago - The Motley Fool

NeoGenomics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81. The post NeoGenomics Shows Market Leadership With Jump To 81 RS Rating appeared first on...

10 months ago - Investors Business Daily

A Relative Strength Rating upgrade for NeoGenomics shows improving technical performance. Will it continue?

11 months ago - Investors Business Daily

Near-term headwinds won’t damage the long-term prospects of these two companies.

Other stocks mentioned: FB
1 year ago - The Motley Fool

The company decided to pull the trigger on a combined offering of stock and debt to pad its balance sheet during uncertain times.

1 year ago - The Motley Fool

Despite experiencing a double-digit decline in test volumes, the cancer genetics lab hasn't furloughed employees. It has even retooled labs to process COVID-19 swab and blood tests.

1 year ago - The Motley Fool

Neogenomics Inc. (NEO) CEO Doug VanOort on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

NeoGenomics (NEO) delivered earnings and revenue surprises of -200.00% and -0.02%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Test volumes fell by double digits at the end of March compared with the year-ago period. How long does management think that trend will continue?

1 year ago - The Motley Fool

Investors should prepare for the genetic testing industry to see a tangible slowdown in volumes due to the coronavirus pandemic.

Other stocks mentioned: EXAS, NVTA
1 year ago - The Motley Fool

Growth stocks have been getting punished in the current market downturn, but investors with a long-term mindset will find plenty to like in the latest earnings report.

1 year ago - The Motley Fool

Advances in precision medicine continue to propel the leader in oncology testing services.

1 year ago - The Motley Fool

The cancer genetics company reported full-year 2019 operating results, but that's probably not the reason for the decline.

1 year ago - The Motley Fool

NeoGenomics, Inc. (NEO) CEO Doug VanOort on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

NeoGenomics (NEO) delivered earnings and revenue surprises of 42.86% and 2.31%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

About NEO

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or... [Read more...]

Industry
Diagnostics & Research
IPO Date
Nov 2, 1999
Stock Exchange
NASDAQ
Ticker Symbol
NEO
Full Company Profile

Financial Performance

In 2020, NeoGenomics's revenue was $444.45 million, an increase of 8.71% compared to the previous year's $408.83 million. Earnings were $4.17 million, a decrease of -47.89%.

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for NeoGenomics stock is "Strong Buy." The 12-month stock price forecast is 60.00, which is an increase of 63.02% from the latest price.

Price Target
$60.00
(63.02% upside)
Analyst Consensus: Strong Buy